Stocks › NKTR
NEKTAR THERAPEUTICS
NKTR·Nasdaq·
United States·USD
United States·USD$39.91
-2.31 (-5.47%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
NKTR
NEKTAR THERAPEUTICS · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
NKTRS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of NKTR by members of U.S. Congress · 4 on record
| Politician | Stock | Type | Filed | Traded | |
|---|---|---|---|---|---|
 Josh GottheimerHouse · D · NJ |
NKTRNEKTAR THERAPEUTICS · Stock |
Sale $1,001 - $15,000 |
Oct 2, 2018 | Jun 21, 2018 | Filing ↗ |
| Josh GottheimerHouse · D · NJ |
NKTRNEKTAR THERAPEUTICS · Stock |
Purchase $1,001 - $15,000 |
Oct 2, 2018 | Jun 6, 2018 | Filing ↗ |
 Eric SwalwellHouse · D · CA |
NKTRNEKTAR THERAPEUTICS · Stock |
Sale $1,001 - $15,000 |
Apr 7, 2015 | Apr 1, 2015 | Filing ↗ |
| Eric SwalwellHouse · D · CA |
NKTRNEKTAR THERAPEUTICS · Stock |
Sale $1,001 - $15,000 |
Feb 27, 2015 | Jan 31, 2015 | Filing ↗ |
Whale Activity
Position changes in NKTR reported for 2026-09-30 by 1 tracked institutional filer
- Increased0
- New0
- Held0
- Decreased0
- Closed0
- No prior filing1
| Filer | Shares | Value | Change |
|---|---|---|---|
| Two Seas Capital LP | 3.3M | $202.6M | — |
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by NKTR insiders, by quarter · Form 4
Recent Insider Transactions
959 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| Zalevsky JonathanChief R&D Officer | Sale | −186 | $71.98 | $13K | Aug 18, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −418 | $71.98 | $30K | Aug 18, 2026 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Sale | −5,681 | $70.00 | $398K | Jun 30, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −4,500 | $61.65 | $277K | Jun 17, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −5,500 | $60.81 | $334K | Jun 17, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −4,697 | $60.71 | $285K | Jun 16, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −5,303 | $59.97 | $318K | Jun 16, 2026 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Sale | −5,538 | $60.71 | $336K | Jun 15, 2026 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Sale | −199 | $65.51 | $13K | May 19, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −444 | $65.51 | $29K | May 19, 2026 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Sale | −180 | $73.00 | $13K | Feb 18, 2026 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −423 | $73.00 | $31K | Feb 18, 2026 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Sale | −3,867 | $35.67 | $138K | Jan 20, 2026 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Grant / award | +6,250 | $0.00 | $0 | Dec 22, 2025 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Grant / award | +21.7K | $0.00 | $0 | Dec 22, 2025 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Sale | −1,157 | n/c | — | Nov 25, 2025 | Form 4 ↗ |
| Wilson Mark AndrewChief Legal Officer | Sale | −630 | n/c | — | Nov 25, 2025 | Form 4 ↗ |
| ROBIN HOWARD WPresident & CEO · Director | Sale | −2,207 | n/c | — | Nov 25, 2025 | Form 4 ↗ |
| Zalevsky JonathanChief R&D Officer | Grant / award | +2,666 | $0.00 | $0 | Nov 21, 2025 | Form 4 ↗ |
| Wilson Mark AndrewChief Legal Officer | Grant / award | +1,903 | $0.00 | $0 | Nov 21, 2025 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding NKTR · SEC Form N-PORT
| Fund | Shares | Value | % of fund | As of |
|---|---|---|---|---|
| Fidelity Growth Company Fund Fidelity Mt. Vernon Street Trust | 1.8M | $119.0M | 0.12% | May 31, 2026 |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VANGUARD INDEX FUNDS | 1.1M | $75.1M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF iShares Trust | 896.1K | $62.6M | 0.08% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund Fidelity Mt. Vernon Street Trust | 492.8K | $32.0M | 0.12% | May 31, 2026 |
| Fidelity Series Growth Company Fund Fidelity Mt. Vernon Street Trust | 419.8K | $27.2M | 0.11% | May 31, 2026 |
| VANGUARD EXTENDED MARKET INDEX FUND VANGUARD INDEX FUNDS | 387.6K | $27.1M | 0.03% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund Fidelity Salem Street Trust | 376.9K | $26.6M | 0.08% | Jul 31, 2026 |
| LORD ABBETT DEVELOPING GROWTH FUND INC LORD ABBETT DEVELOPING GROWTH FUND, INC. | 273.9K | $23.3M | 1.05% | Apr 30, 2026 |
| iShares Russell 2000 Growth ETF iShares Trust | 285.3K | $19.9M | 0.13% | Jun 30, 2026 |
| Invesco Main Street Small Cap Fund AIM GROWTH SERIES (INVESCO GROWTH SERIES) | 181.9K | $13.1M | 0.59% | Mar 31, 2026 |
Mutual funds and ETFs whose N-PORT filings list NKTR's shares (CUSIP 640268306), each fund at its latest report since Mar 7, 2026, largest positions first. Bonds, options and short positions are left out.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
- Sina ToussiSCHEDULE 13G/A · passive (13G) · 3.3M shares9.8%
Sep 28, 2026 · ↗ - Two Seas Capital GP LLCSCHEDULE 13G/A · passive (13G) · 3.3M shares9.8%
Sep 28, 2026 · ↗ - Two Seas Capital LPSCHEDULE 13G/A · passive (13G) · 3.3M shares9.8%
Sep 28, 2026 · ↗ - Sina ToussiSCHEDULE 13G/A · passive (13G) · 3.1M shares9.1%
Aug 14, 2026 · ↗ - Two Seas Capital GP LLCSCHEDULE 13G/A · passive (13G) · 3.1M shares9.1%
Aug 14, 2026 · ↗ - Two Seas Capital LPSCHEDULE 13G/A · passive (13G) · 3.1M shares9.1%
Aug 14, 2026 · ↗ - BVF INC/ILSCHEDULE 13G/A · passive (13G) · 2.4M shares7.1%
Aug 14, 2026 · ↗ - BVF PARTNERS L P/ILSCHEDULE 13G/A · passive (13G) · 2.4M shares7.1%
Aug 14, 2026 · ↗ - BVF GP HOLDINGS LLCSCHEDULE 13G/A · passive (13G) · 2.2M shares6.5%
Aug 14, 2026 · ↗ - BVF Partners OS Ltd.SCHEDULE 13G/A · passive (13G) · 157.5K shares0.5%
Aug 14, 2026 · ↗
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming nektar therapeutics as client
No lobbying filings found naming NEKTAR THERAPEUTICS as the client.
- BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2022 Q2 · HCR—
Filing ↗ - BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2022 Q1 · HCR$50K
Filing ↗ - BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2021 Q4 · HCR$50K
Filing ↗ - BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2021 Q3 · HCR$50K
Filing ↗ - BGR GOVERNMENT AFFAIRSNEKTAR THERAPEUTICS · 2021 Q2 · HCR$50K
Filing ↗
Government Contracts
Federal awards to NEKTAR THERAPEUTICS · USAspending
No federal contract awards found for NEKTAR THERAPEUTICS.
U.S. Patents
Recent USPTO applications naming NEKTAR THERAPEUTICS
No USPTO patent applications found for NEKTAR THERAPEUTICS.
Annual Financials
From NKTR's 10-K filings · XBRL
No annual XBRL figures on record for NKTR. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 1-for-15Reverse splitJun 9, 2025
- 2-for-1Stock splitAug 23, 2000
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
- 8-K · Items 7.01, 9.01Reg FD disclosureOct 1, 2026
EDGAR ↗ - 8-K · Items 8.01Other eventsSep 25, 2026
EDGAR ↗ - 8-K · Items 7.01, 9.01Reg FD disclosureSep 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsAug 13, 2026
EDGAR ↗ - 8-K · Items 5.07Shareholder voteJun 5, 2026
EDGAR ↗ - 8-K · Items 1.01, 5.02, 9.01Material agreement · Officer / director changeMay 8, 2026
EDGAR ↗ - 8-K · Items 2.02, 9.01Results of operationsMay 7, 2026
EDGAR ↗
About NEKTAR THERAPEUTICS
From SEC EDGAR company records
Industry (SIC 2834)Pharmaceutical Preparations
SectorHealthcare
HeadquartersSAN FRANCISCO, CA
IncorporatedDE
SEC CIK0000906709 ↗
Former namesINHALE THERAPEUTIC SYSTEMS INC, INHALE THERAPEUTIC SYSTEMS